| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 11 securities · may seek to influence control | ||||||
|
Trinity Biotech plc
13D/A
TRIB · 896438603
|
10.0% |
11/10/2026
Event 11/6/2026
|
||||
| Perceptive Advisors LLC | 10.0% | |||||
| Perceptive Credit Advisors LLC | 10.0% | |||||
| Joseph Edelman | 10.0% | |||||
| Perceptive Credit Holdings II, L.P. | 10.0% | |||||
| Perceptive Credit Holdings III, L.P. | 10.0% | |||||
|
Nautilus Biotechnology, Inc.
13D/A
NAUT · 63909J108
|
3.9% |
11/3/2026
Event 10/5/2026
|
||||
| Perceptive Advisors LLC | 3.9% | |||||
| Joseph Edelman | 3.9% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 3.8% | |||||
| C2 Life Sciences LLC | 0.1% | |||||
|
LeonaBio, Inc.
13D/A
LONA · 04746L203
|
20.0% |
10/26/2026
Event 10/26/2026
|
||||
| Perceptive Advisors LLC | 20.0% | |||||
| Joseph Edelman | 20.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 16.5% | |||||
| Perceptive Xontogeny Venture Fund II, LP | 3.8% | |||||
|
Kardigan, Inc.
13D/A
KARD · 485925101
|
8.8% |
10/1/2026
Event 9/29/2026
|
||||
| Perceptive Advisors LLC | 8.8% | |||||
| Joseph Edelman | 8.8% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 2.7% | |||||
| Perceptive Capital Solutions Holdings LP | 6.2% | |||||
|
Immatics N.V.
13D/A
IMTX · N44445109
|
7.6% |
8/27/2026
Event 8/26/2026
|
||||
| Perceptive Advisors LLC | 7.6% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.6% | |||||
| Joseph Edelman | 7.6% | |||||
|
Solid Biosciences Inc.
13D/A
SLDB · 83422E204
|
11.2% |
8/14/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 11.2% | |||||
| Joseph Edelman | 11.2% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 11.2% | |||||
| Perceptive Xontogeny Venture Fund, LP | 0.1% | |||||
|
Trinity Biotech plc
13D/A
TRIB · 896438504
|
9.9% |
5/4/2026
Event 4/30/2026
|
||||
| Perceptive Advisors LLC | 9.9% | |||||
| Perceptive Credit Advisors LLC | 9.9% | |||||
| Joseph Edelman | 9.9% | |||||
| Perceptive Credit Holdings II, L.P. | 9.9% | |||||
| Perceptive Credit Holdings III, L.P. | 9.9% | |||||
|
MeiraGTx Holdings plc
13D/A
MGTX · G59665102
|
12.6% |
4/24/2026
Event 4/17/2026
|
||||
| Perceptive Advisors LLC | 12.6% | |||||
| Joseph Edelman | 12.6% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 12.6% | |||||
|
Astria Therapeutics, Inc.
13D/A
ATXS · 04635X102
|
0% |
2/9/2026
Event 1/26/2026
|
||||
| Perceptive Advisors LLC | 0% | |||||
| Joseph Edelman | 0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||||
| Perceptive Xontogeny Venture Fund, L.P. | 0% | |||||
|
Lyra Therapeutics, Inc.
13D/A
LYRA · 55234L204
|
0% |
11/25/2025
Event 11/21/2025
|
||||
| Perceptive Advisors LLC | 0% | |||||
| Joseph Edelman | 0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||||
| Perceptive LS (A), LLC | 0% | |||||
|
Lyra Therapeutics, Inc.
13D/A
LYRA · 55234L105
|
15.6% |
8/14/2025
Event 8/12/2025
|
||||
| Perceptive Advisors LLC | 15.6% | |||||
| Joseph Edelman | 15.6% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 14.0% | |||||
| Perceptive LS (A), LLC | 1.6% | |||||
| Schedule 13G · 66 securities · passive | ||||||
|
Yarrow Bioscience, Inc.
13G/A
YARW · 92941V407
|
10.0% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 10.0% | |||||
| Joseph Edelman | 10.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | |||||
|
Sutro Biopharma, Inc.
13G/A
STRO · 869367201
|
5.8% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 5.8% | |||||
| Joseph Edelman | 5.8% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.8% | |||||
|
Research Alliance Corporation IV
13G/A
RACD · G75228109
|
9.0% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 9.0% | |||||
| Joseph Edelman | 9.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 9.0% | |||||
|
Research Alliance Corporation III
13G/A
RACC · G75226103
|
0% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 0% | |||||
| Joseph Edelman | 0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||||
|
Orchestra BioMed Holdings, Inc.
13G/A
OBIO · 68572M106
|
8.2% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 8.2% | |||||
| Joseph Edelman | 8.2% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.2% | |||||
|
Nurix Therapeutics, Inc.
13G/A
NRIX · 67080M103
|
4.9% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 4.9% | |||||
| Joseph Edelman | 4.9% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.9% | |||||
|
Invivyd, Inc.
13G/A
IVVD · 00534A102
|
4.7% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 4.7% | |||||
| Joseph Edelman | 4.7% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.7% | |||||
|
Opus Genetics, Inc.
13G/A
IRD · 67577R102
|
10.0% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 10.0% | |||||
| Joseph Edelman | 10.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | |||||
|
Freenome, Inc.
13G/A
FRNM · 35661P100
|
11.3% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 11.3% | |||||
| Joseph Edelman | 11.3% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 11.2% | |||||
| C2 Life Sciences LLC | 0.1% | |||||
|
enGene Therapeutics Inc.
13G/A
ENGN · 29286X101
|
8.9% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 8.9% | |||||
| Joseph Edelman | 8.9% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.9% | |||||
|
Edesa Biotech, Inc.
13G/A
EDSA · 27966L306
|
4.2% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 4.2% | |||||
| Joseph Edelman | 4.2% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.2% | |||||
|
Amylyx Pharmaceuticals, Inc.
13G/A
AMLX · 03237H101
|
8.2% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 8.2% | |||||
| Joseph Edelman | 8.2% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.2% | |||||
|
Adagio Medical Holdings, Inc.
13G/A
00534B308
|
44.4% |
11/16/2026
Event 9/30/2026
|
||||
| Perceptive Advisors LLC | 44.4% | |||||
| Joseph Edelman | 44.4% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 43.9% | |||||
| C2 Life Sciences LLC | 0.7% | |||||
|
IRulya Therapeutics Inc.
13G
IRLA · 22053A305
|
8.4% |
10/14/2026
Event 10/6/2026
|
||||
| Perceptive Advisors LLC | 8.4% | |||||
| Joseph Edelman | 8.4% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.4% | |||||
|
Spyre Therapeutics, Inc.
13G/A
SYRE · 00773J202
|
4.9% |
8/14/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 4.9% | |||||
| Joseph Edelman | 4.9% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.9% | |||||
|
X4 Pharmaceuticals, Inc.
13G/A
XFOR · 98420X202
|
8.1% |
8/14/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 8.1% | |||||
| Joseph Edelman | 8.1% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.1% | |||||
|
Tenax Therapeutics, Inc.
13G/A
TENX · 88032L605
|
4.5% |
8/14/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 4.5% | |||||
| Joseph Edelman | 4.5% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.5% | |||||
|
SAB Biotherapeutics, Inc.
13G/A
SABS · 78397T202
|
7.3% |
8/14/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 7.3% | |||||
| Joseph Edelman | 7.3% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.3% | |||||
|
enVVeno Medical Corporation
13G/A
NVNO · 29415J205
|
3.5% |
8/14/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 3.5% | |||||
| Joseph Edelman | 3.5% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 3.5% | |||||
|
Inhibrx Biosciences, Inc.
13G/A
INBX · 45720N103
|
10.0% |
8/14/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 10.0% | |||||
| Joseph Edelman | 10.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | |||||
|
Inhibikase Therapeutics, Inc.
13G/A
IKT · 45719W205
|
6.9% |
8/14/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 6.9% | |||||
| Joseph Edelman | 6.9% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 6.9% | |||||
|
enGene Holdings Inc.
13G/A
ENGN · 29286M105
|
10.0% |
8/14/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 10.0% | |||||
| Joseph Edelman | 10.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | |||||
|
BlossomHill Therapeutics, Inc.
13G
BLSM · 095130100
|
5.9% |
8/14/2026
Event 8/7/2026
|
||||
| Perceptive Advisors LLC | 5.9% | |||||
| Joseph Edelman | 5.9% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.9% | |||||
|
Alto Neuroscience, Inc.
13G/A
ANRO · 02157Q109
|
10.0% |
8/14/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 10.0% | |||||
| Joseph Edelman | 10.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | |||||
|
Relay Therapeutics, Inc.
13G/A
RLAY · 75943R102
|
6.4% |
8/10/2026
Event 6/30/2026
|
||||
| Perceptive Advisors LLC | 6.4% | |||||
| Joseph Edelman | 6.4% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 6.4% | |||||
|
Kiora Pharmaceuticals, Inc.
13G
KPRX · 49721T507
|
10.0% |
8/10/2026
Event 4/6/2026
|
||||
| Perceptive Advisors LLC | 10.0% | |||||
| Joseph Edelman | 10.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | |||||
|
Palisade Bio, Inc.
13G/A
PALI · 696389402
|
7.9% |
5/15/2026
Event 3/31/2026
|
||||
| Perceptive Advisors LLC | 7.9% | |||||
| Joseph Edelman | 7.9% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.9% | |||||
|
Adagio Medical Holdings, Inc.
13G/A
ADGM · 00534B100
|
55.4% |
5/15/2026
Event 3/31/2026
|
||||
| Perceptive Advisors LLC | 55.4% | |||||
| Joseph Edelman | 55.4% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 54.7% | |||||
| C2 Life Sciences LLC | 0.9% | |||||
|
Biodesix, Inc.
13G/A
BDSX · 09075X207
|
4.6% |
5/15/2026
Event 3/31/2026
|
||||
| Perceptive Advisors LLC | 4.6% | |||||
| Joseph Edelman | 4.6% | |||||
| Perceptive Credit Advisors LLC | 4.6% | |||||
| Pcof Eq Aiv IV, LP | 0.5% | |||||
| Perceptive Credit Holdings IV, LP | 4.1% | |||||
|
Traws Pharma, Inc.
13G/A
TRAW · 68232V884
|
6.1% |
5/15/2026
Event 3/31/2026
|
||||
| Perceptive Advisors LLC | 6.1% | |||||
| Joseph Edelman | 6.1% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 6.1% | |||||
|
Rhythm Pharmaceuticals, Inc.
13G/A
RYTM · 76243J105
|
5.1% |
5/15/2026
Event 3/31/2026
|
||||
| Perceptive Advisors LLC | 5.1% | |||||
| Joseph Edelman | 5.1% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.1% | |||||
| Perceptive Capital Solutions Holdings LP | 1.1% | |||||
|
Aldeyra Therapeutics, Inc.
13G/A
ALDX · 01438T106
|
0% |
5/15/2026
Event 3/31/2026
|
||||
| Perceptive Advisors LLC | 0% | |||||
| Joseph Edelman | 0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||||
|
CytomX Therapeutics, Inc.
13G/A
CTMX · 23284F105
|
4.6% |
5/15/2026
Event 3/31/2026
|
||||
| Perceptive Advisors LLC | 4.6% | |||||
| Joseph Edelman | 4.6% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.6% | |||||
|
Avalyn Pharma Inc.
13G
AVLN · 05348Y105
|
6.0% |
5/7/2026
Event 4/30/2026
|
||||
| Perceptive Advisors LLC | 6.0% | |||||
| Joseph Edelman | 6.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 1.0% | |||||
| Perceptive Xontogeny Venture Fund II, L.P | 5.1% | |||||
|
Zymeworks Inc.
13G
ZYME · 98985Y108
|
5.4% |
4/15/2026
Event 4/8/2026
|
||||
| Perceptive Advisors LLC | 5.4% | |||||
| Joseph Edelman | 5.4% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.4% | |||||
|
Kiora Pharmaceuticals, Inc.
13G
KPRX · 49721T507
|
10.0% |
4/13/2026
Event 4/6/2026
|
||||
| Perceptive Advisors LLC | 10.0% | |||||
| Joseph Edelman | 10.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | |||||
|
Celcuity Inc.
13G/A
CELC · 15102K100
|
6.8% |
2/17/2026
Event 12/31/2025
|
||||
| Perceptive Advisors LLC | 6.8% | |||||
| Joseph Edelman | 6.8% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 6.8% | |||||
|
enVVeno Medical Corporation
13G/A
NVNO · 29415J106
|
10.0% |
2/17/2026
Event 12/31/2025
|
||||
| Perceptive Advisors LLC | 10.0% | |||||
| Joseph Edelman | 10.0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | |||||
|
Praxis Precision Medicines, Inc.
13G/A
PRAX · 74006W207
|
7.2% |
2/17/2026
Event 12/31/2025
|
||||
| Perceptive Advisors LLC | 7.2% | |||||
| Joseph Edelman | 7.2% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.2% | |||||
|
Travere Therapeutics, Inc.
13G/A
TVTX · 89422G107
|
4.8% |
2/17/2026
Event 12/31/2025
|
||||
| Perceptive Advisors LLC | 4.8% | |||||
| Joseph Edelman | 4.8% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.8% | |||||
|
Bright Minds Biosciences Inc.
13G/A
DRUG · 10919W405
|
4.6% |
2/17/2026
Event 12/31/2025
|
||||
| Perceptive Advisors LLC | 4.6% | |||||
| Joseph Edelman | 4.6% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.6% | |||||
|
Artivion, Inc.
13G/A
AORT · 228903100
|
4.3% |
11/14/2025
Event 9/30/2025
|
||||
| Perceptive Advisors LLC | 4.3% | |||||
| Joseph Edelman | 4.3% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.3% | |||||
|
KALA BIO, Inc.
13G/A
KALA · 483119202
|
0% |
11/14/2025
Event 9/30/2025
|
||||
| Perceptive Advisors LLC | 0% | |||||
| Joseph Edelman | 0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||||
|
Inventiva S.A.
13G/A
IVA · 46124U107
|
4.99% |
11/14/2025
Event 9/30/2025
|
||||
| Perceptive Advisors LLC | 4.99% | |||||
| Joseph Edelman | 4.99% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.99% | |||||
|
Verona Pharma plc
13G/A
VRNA · 925050106
|
0% |
11/14/2025
Event 9/30/2025
|
||||
| Perceptive Advisors LLC | 0% | |||||
| Joseph Edelman | 0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||||
|
OnKure Therapeutics, Inc.
13G/A
OKUR · 68277Q105
|
0% |
8/14/2025
Event 6/30/2025
|
||||
| Perceptive Advisors LLC | ||||||
| Joseph Edelman | 0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||||
|
Contineum Therapeutics, Inc.
13G/A
CTNM · 21217B100
|
3.2% |
8/14/2025
Event 6/30/2025
|
||||
| Perceptive Advisors LLC | 3.2% | |||||
| Joseph Edelman | 3.2% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 3.2% | |||||
|
Amicus Therapeutics, Inc.
13G/A
FOLD · 03152W109
|
2.4% |
8/14/2025
Event 6/30/2025
|
||||
| Perceptive Advisors LLC | 2.4% | |||||
| Joseph Edelman | 2.4% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 2.4% | |||||
|
Edgewise Therapeutics, Inc.
13G/A
EWTX · 28036F105
|
4.4% |
8/14/2025
Event 6/30/2025
|
||||
| Perceptive Advisors LLC | 4.4% | |||||
| Joseph Edelman | 4.4% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.4% | |||||
|
Anteris Technologies Global Corp.
13G/A
AVR · 03675P102
|
4.7% |
8/14/2025
Event 6/30/2025
|
||||
| Perceptive Advisors LLC | 4.7% | |||||
| Joseph Edelman | 4.7% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.7% | |||||
|
Evolus, Inc.
13G/A
EOLS · 30052C107
|
3.8% |
8/14/2025
Event 6/30/2025
|
||||
| Perceptive Advisors LLC | 3.8% | |||||
| Joseph Edelman | 3.8% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 3.8% | |||||
|
Arcellx, Inc.
13G/A
ACLX · 03940C100
|
4.5% |
8/14/2025
Event 6/30/2025
|
||||
| Perceptive Advisors LLC | 4.5% | |||||
| Joseph Edelman | 4.5% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.5% | |||||
|
Beta Bionics, Inc.
13G/A
BBNX · 08659B102
|
3.7% |
8/7/2025
Event 3/31/2025
|
||||
| Perceptive Advisors LLC | 3.7% | |||||
| Joseph Edelman | 3.7% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 3.7% | |||||
|
Acrivon Therapeutics, Inc.
13G/A
ACRV · 004890109
|
0% |
6/4/2025
Event 6/2/2025
|
||||
| Perceptive Advisors LLC | 0% | |||||
| Joseph Edelman | 0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||||
|
Verrica Pharmaceuticals, Inc.
13G/A
VRCA · 92511W108
|
1.6% |
5/15/2025
Event 3/31/2025
|
||||
| Perceptive Advisors LLC | 1.6% | |||||
| Joseph Edelman | 1.6% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 1.6% | |||||
|
Outset Medical, Inc.
13G/A
OM · 690145206
|
6.7% |
5/15/2025
Event 3/31/2025
|
||||
| Perceptive Advisors LLC | 6.7% | |||||
| Joseph Edelman | 6.7% | |||||
| Perceptive Credit Advisors, LLC | 6.7% | |||||
| Perceptive Credit Holdings IV, LP | 6.7% | |||||
|
Surrozen, Inc.
13G/A
SRZN · 86889P208
|
1.9% |
5/15/2025
Event 3/31/2025
|
||||
| Perceptive Advisors LLC | 1.9% | |||||
| Joseph Edelman | 1.9% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 1.9% | |||||
|
Ensysce Biosciences, Inc.
13G/A
ENSC · 293602504
|
3.7% |
5/15/2025
Event 3/31/2025
|
||||
| Perceptive Advisors LLC | 3.7% | |||||
| Joseph Edelman | 3.7% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 3.7% | |||||
|
Biodesix, Inc.
13G
BDSX · 09075X108
|
5.1% |
5/15/2025
Event 5/12/2025
|
||||
| Perceptive Advisors LLC | 5.1% | |||||
| Joseph Edelman | 5.1% | |||||
| Perceptive Credit Advisors LLC | 5.1% | |||||
| Pcof Eq Aiv IV, LP | 0.8% | |||||
| Perceptive Credit Holdings IV, LP | 4.3% | |||||
|
Instil Bio, Inc.
13G/A
TIL · 45783C200
|
0% |
5/15/2025
Event 3/31/2025
|
||||
| Perceptive Advisors LLC | 0% | |||||
| Joseph Edelman | 0% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||||
|
Iovance Biotherapeutics, Inc.
13G/A
IOVA · 462260100
|
3.8% |
5/15/2025
Event 3/31/2025
|
||||
| Perceptive Advisors LLC | 3.8% | |||||
| Joseph Edelman | 3.8% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 3.8% | |||||
|
CARGO Therapeutics, Inc.
13G/A
CRGX · 14179K101
|
2.5% |
4/23/2025
Event 4/23/2025
|
||||
| Perceptive Advisors LLC | 2.5% | |||||
| Joseph Edelman | 2.5% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||||
| Perceptive Xontogeny Venture Fund II, L.P. | 2.5% | |||||
|
Outset Medical, Inc.
13G
OM · 690145107
|
9.5% |
2/28/2025
Event 1/8/2025
|
||||
| Perceptive Advisors LLC | 9.5% | |||||
| Joseph Edelman | 9.5% | |||||
| Perceptive Credit Advisors LLC | 9.5% | |||||
| Perceptive Credit Holdings IV, LP | 9.5% | |||||
|
Forte Biosciences, Inc.
13G/A
FBRX · 34962G208
|
2.5% |
2/14/2025
Event 12/31/2024
|
||||
| Perceptive Advisors LLC | 2.5% | |||||
| Joseph Edelman | 2.5% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 2.5% | |||||
|
Applied Therapeutics, Inc.
13G/A
APLT · 03828A101
|
2.4% |
2/14/2025
Event 12/31/2024
|
||||
| Perceptive Advisors LLC | 2.4% | |||||
| Joseph Edelman | 2.4% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 2.4% | |||||
|
RAPT Therapeutics, Inc.
13G/A
RAPT · 75382E109
|
4.5% |
2/14/2025
Event 12/31/2024
|
||||
| Perceptive Advisors LLC | 4.5% | |||||
| Joseph Edelman | 4.5% | |||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.